Resolute Onyx™ is a drug-eluting stent (DES) that's different by design, which makes it optimized for complex PCI. It's safe and effective in real-world, high bleeding risk patients on 1-month DAPT.1Download Brochure
Resolute Onyx DES is proven safe and effective in high bleeding risk (HBR) patients with 1-month DAPT labeling, based on results from the Onyx ONE Clear Analysis.2
DAPT duration decisions are best made on an individual basis. Premature discontinuation or interruption of prescribed antiplatelet medication could result in a higher risk of ST, MI, or death.
Single-wire Design — increasing conformability and apposition3
BioLinx™ Polymer — offering superior thromboresistance4
Resolute Onyx DES is composed of a single-wire strand formed into a continuous sinusoidal waveform, providing a fluid range of motion with greater flexibility and conformability when compared to laser-cut stents.3
Single-wire design increases deliverability, flexibility, conformability, wall apposition, and may reduce arterial injury and thrombus formation.3-5
The platinum-iridium core within Resolute Onyx DES increases radiopacity for accurate stent placement.
Higher Is Better
Resolute Onyx DES is designed with rounded struts that may create a smooth passage for side branch access.5
Square Strut Cross-section
Regular Cell Shape
Resolute Onyx DES
Irregular Cell Shape
Xience Sierra DES
The broad Resolute Onyx DES size matrix optimizes stent deployment, now with greater expansion capabilities.
4.50 and 5.00 mm sizes now able to expand up to 6.00 mm‡2
2.00 mm size now able to expand up to 3.50 mm‡2
Watch a short video to learn more about the BioLinx polymer.
The Resolute Onyx DES zotarolimus drug effectively inhibits neointimal growth while the exclusive, highly biocompatible BioLinx polymer contributes to minimal inflammation, low thrombotic risk,6 as well as rapid, complete, and functional endothelial healing.§5
The one-month optical coherence tomography (OCT) study investigated early vessel healing in patients with complex coronary artery disease treated with Resolute Onyx DES.
92.3% Stent Coverage at One Month7
Third-party brands are trademarks of their respective owners.
Including Resolute Integrity™ DES, part of the Medtronic DES portfolio.
Resolute Onyx stents should not be expanded to a diameter beyond the maximum labeled diameter listed per the IFU. Post-dilation required for overexpansion.
In porcine models.
Windecker S, Latib A, Kedhi E, et al. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. N Engl J Med. March 26, 2020;382(13):1208-1218.
Resolute Onyx DES, instructions for use.
Shown in independent assessment. Data on file at Medtronic.
Jinnouchi H, Sato Y, Cheng Q, et al. Thromboresistance and endothelial healing in polymer-coated versus polymer-free drug-eluting stents: Implications for short-term dual anti-platelet therapy. Int J Cardiol. March 15, 2021;327:52-57.
Based on bench test data on file at Medtronic. May not be indicative of clinical performance.
Silber S, Kirtane AJ, Belardi JA, et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur Heart J. August 1, 2014;35(29):1949-1956.
Roleder T, Kedhi E, Berta B, et al. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. Adv Interv Cardiol. 2019;15(2):143-150.